Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study
Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study
复制标题
DOI：
10.1111/j.1600-0560.2010.01505.x
复制
发表时间：
2010-04-01
影响因子：
1.7
通讯作者：
Duncan, Lyn M.
中科院分区：
文献类型：
--
作者：
Nazarian, Rosalynn M.;Prieto, Victor G.;Duncan, Lyn M.
方法：TMA包含480例良性痣、原发性皮肤黑色素瘤和转移性黑色素瘤。免疫组化检测黑色素瘤生物标志物，包括c-Kit、MITF、MART-1、HMB-45和bcl-2。结果：在83%的痣，56%的原发性黑色素瘤和23%的转移瘤中观察到强烈的MITF蛋白染色。Bcl-2的表达随着转移的进展而降低（分别在新生瘤、原发瘤和转移瘤中检测到的比例分别为86%、89%和52%），与MART-1相反，后者没有差异表达（74%、85%和84%）。HMB-45在18%的痣和大多数（72%和75%）原发性黑色素瘤和转移瘤中被观察到。c-Kit蛋白随着从痣到原发肿瘤的进展而增加（分别占10%和77%），在转移瘤中减少（占26%）。结论：通过国家癌症研究所（NCI）器官系统分会赞助的皮肤孢子的合作，我们确定了一份感兴趣的黑色素瘤生物标志物清单，开发了黑色素细胞肿瘤进展TMA，并完成了这些生物标志物的协调分析。该TMA通过揭示肿瘤进展过程中生物标志物的表达趋势和确认皮肤黑色素细胞肿瘤中生物标志物表达的异质性，已成为新发现和已知黑色素瘤生物标志物的强大验证工具。Nazarian RM, Prieto VG, Elder DE, Duncan LM。黑色素瘤生物标志物在黑色素细胞肿瘤进展中的表达：组织微阵列研究。
Methods: The TMA contains 480 cores of benign nevi, primary cutaneous melanoma and melanoma metastases. Immunohistochemical detection of melanoma biomarkers, including c-Kit, MITF, MART-1, HMB-45 and bcl-2 was performed.Results: Intense nuclear staining for MITF protein was observed in 83% of nevi, 56% of primary melanomas and 23% of metastases. Bcl-2 expression was reduced with progression to metastasis (detected in 86, 89 and 52% of nevi, primaries and metastases, respectively), contrary to MART-1, which showed no differential expression (74, 85 and 84%). HMB-45 was observed in 18% of nevi and most (72 and 75%) primary melanomas and metastases. c-Kit protein increased with progression from nevi to primary tumor (10 and 77% of cases, respectively) and was decreased in metastases (26% of cases).Conclusions: Through a collaboration of the Skin SPOREs sponsored by the Organ Systems Branch of the National Cancer Institute (NCI), we identified a list of melanoma biomarkers of interest, developed a melanocytic tumor progression TMA and completed a coordinated analysis of these biomarkers. This TMA has served as a powerful validation tool for newly identified and known melanoma biomarkers by revealing trends in expression during tumor progression and by confirming the heterogeneity of biomarker expression in cutaneous melanocytic tumors.Nazarian RM, Prieto VG, Elder DE, Duncan LM. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.